BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia.

ABSTRACT:

Background

Established genetic biomarkers in chronic lymphocytic leukemia (CLL) have been useful in predicting response to chemoimmunotherapy but are less predictive of response to targeted therapies. With several such targeted therapies now approved for CLL, identifying novel, non-genetic predictive biomarkers of response may help to select the optimal therapy for individual patients.

Methods

We coupled data from a functional precision medicine technique called BH3-profiling, which assesses cellular cytochrome c loss levels as indicators for survival dependence on anti-apoptotic proteins, with multi-omics data consisting of targeted and whole-exome sequencing, genome-wide DNA methylation profiles, RNA-sequencing, protein and functional analyses, to identify biomarkers for t

SUBMITTER: Chong SJF 

PROVIDER: S-EPMC11874845 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature